Sjödahl Gottfrid
Division of Urological Research, Department of Translational Medicine, Lund University, Box 117, SE-221 00, Lund, Sweden.
Methods Mol Biol. 2018;1655:53-64. doi: 10.1007/978-1-4939-7234-0_5.
Molecular subtypes of bladder cancer (BC) can be determined by relatively small immunohistochemistry panels both for non-muscle invasive (NMI) and muscle invasive (MI) tumors. For analysis of NMI tumors, as few as two markers are needed, although classification is dependent also on pathological grade and histological evaluation. The result is a classification into the three tumor-cell phenotypes of NMI-BC, Urothelial-like (Uro), Genomically Unstable (GU), and Basal/SCC-like. For analysis of MI tumors, 13 markers are needed. The larger number of markers required for the classification of MI-BC reflects the inclusion of two additional phenotypes exclusively found in invasive tumors; Mesenchymal-like (Mes-like) and Small-cell/Neuroendocrine-like (Sc/NE-like). Here follows a description of how to perform and approach IHC-based subtype classification of bladder cancer.
膀胱癌（BC）的分子亚型可通过相对较小的免疫组化检测面板来确定，无论是对于非肌层浸润性（NMI）肿瘤还是肌层浸润性（MI）肿瘤。对于NMI肿瘤的分析，尽管分类也依赖于病理分级和组织学评估，但只需少量两种标志物。结果是将NMI-BC分为三种肿瘤细胞表型：尿路上皮样（Uro）、基因组不稳定型（GU）和基底/鳞状细胞样。对于MI肿瘤的分析，则需要13种标志物。MI-BC分类所需的标志物数量较多，这反映了在浸润性肿瘤中专门发现的另外两种表型的纳入；间充质样（Mes样）和小细胞/神经内分泌样（Sc/NE样）。以下是关于如何进行基于免疫组化的膀胱癌亚型分类及方法的描述。
